Senti Biosciences Inc
SNTI3.170USD
-0.470-12.91%
Close 04/29, 16:00（ET）Quotes delayed by 15 min
15.31MMarket Cap
LossP/E TTM
More Details of Senti Biosciences Inc Company
Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.
Company Info
Company codeSNTI
Company nameSenti Biosciences Inc
IPO dateMay 26, 2021
Founded at2021
CEODr. Timothy (Tim) Lu, M.D., Ph.D.
Number of employees34
Security typeOrdinary Share
Fiscal year-endMay 26
Address2 Corporate Drive, First Floor
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94080
Phone16503823281
Websitehttps://www.sentibio.com/
Company codeSNTI
IPO dateMay 26, 2021
Founded at2021
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Kanya Rajangam, M.D., Ph.D.
Dr. Kanya Rajangam, M.D., Ph.D.
President, Head - Research and Development, Chief Medical Officer
President, Head - Research and Development, Chief Medical Officer
33.00K
--
Dr. James J. (Jim) Collins, Ph.D.
Dr. James J. (Jim) Collins, Ph.D.
Independent Director
Independent Director
17.61K
--
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ed T. Mathers ,
Ed T. Mathers ,
Independent Director
Independent Director
--
--
Mr. Donald Tang
Mr. Donald Tang
Director
Director
--
--
Mr. Jay Cross
Mr. Jay Cross
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
--
--
Mr. Feng Hsiung
Mr. Feng Hsiung
Director
Director
--
--
Ms. Fran Schulz
Ms. Fran Schulz
Director
Director
--
--
Dr. Brenda Cooperstone, M.D.
Dr. Brenda Cooperstone, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Kanya Rajangam, M.D., Ph.D.
Dr. Kanya Rajangam, M.D., Ph.D.
President, Head - Research and Development, Chief Medical Officer
President, Head - Research and Development, Chief Medical Officer
33.00K
--
Dr. James J. (Jim) Collins, Ph.D.
Dr. James J. (Jim) Collins, Ph.D.
Independent Director
Independent Director
17.61K
--
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ed T. Mathers ,
Ed T. Mathers ,
Independent Director
Independent Director
--
--
Mr. Donald Tang
Mr. Donald Tang
Director
Director
--
--
Mr. Jay Cross
Mr. Jay Cross
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sun, Apr 13
Update time: Sun, Apr 13
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Celadon Partners SPV 24
37.60%
Bayer HealthCare LLC
10.81%
PharmaEssentia Corp.
8.12%
Armistice Capital LLC
2.06%
Nantahala Capital Management, LLC
1.96%
Other
39.46%
Shareholder Statistics
Shareholder
Proportion
Celadon Partners SPV 24
37.60%
Bayer HealthCare LLC
10.81%
PharmaEssentia Corp.
8.12%
Armistice Capital LLC
2.06%
Nantahala Capital Management, LLC
1.96%
Other
39.46%
Type
Shareholder
Proportion
Corporation
56.52%
Hedge Fund
4.22%
Venture Capital
1.70%
Investment Advisor
1.07%
Individual Investor
0.86%
Investment Advisor/Hedge Fund
0.52%
Research Firm
0.05%
Other
35.06%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
57
25.24M
97.04%
+22.95M
2024Q4
55
2.74M
57.01%
+442.53K
2024Q3
56
2.03M
44.31%
-591.63K
2024Q2
59
2.00M
43.68%
-736.88K
2024Q1
91
2.11M
47.03%
-1.57M
2023Q4
97
2.11M
47.62%
-1.61M
2023Q3
101
2.43M
55.03%
-1.49M
2023Q2
105
2.45M
55.45%
-1.56M
2023Q1
104
2.49M
56.56%
-1.49M
2022Q4
103
2.61M
59.63%
-1.20M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Celadon Partners SPV 24
9.78M
37.6%
+9.78M
--
Mar 18, 2025
Bayer HealthCare LLC
2.81M
10.81%
+2.22M
+377.99%
Mar 10, 2025
Armistice Capital LLC
536.01K
2.06%
+536.01K
--
Dec 31, 2024
Nantahala Capital Management, LLC
509.28K
1.96%
+509.28K
--
Dec 31, 2024
New Enterprise Associates (NEA)
442.62K
1.7%
--
--
Dec 31, 2024
8VC GP I, LLC
253.75K
0.98%
--
--
Dec 31, 2024
Lu (Timothy K M.D., Ph.D.)
799.52K
3.07%
+642.36K
+408.73%
Mar 07, 2025
The Vanguard Group, Inc.
97.47K
0.37%
--
--
Dec 31, 2024
Renaissance Technologies LLC
51.60K
0.2%
+51.60K
--
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
ARK Genomic Revolution ETF
0%
ARK Genomic Revolution ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1
Date
Type
Ratio
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1